XML 46 R35.htm IDEA: XBRL DOCUMENT v3.26.1
Basis of Presentation (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Product Information [Line Items]    
Research and development expense $ 484,873 $ 294,479
Conversion of preferred shares 8,044,884  
Operating loss carryforwards $ 3,903,551  
Net operating losses carryforwards, expire date begin to expire in 2027  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]    
Product Information [Line Items]    
Concentration risk percentage 16.70% 10.20%